The Global ADHD Attention Deficit Hyperactivity Disorder Drugs Therapeutics Market Offers A Vast Spectrum of Opportunities to Different Product Developers and Services Providers Including Industries, Vendors, And Firms to Develop and Grow In The Market At A Universal Level. Global ADHD Therapeutics Information, By Drug Types (Stimulants and Non-Stimulants), By Distribution Channels (Hospitals, Clinics, Pharmacies, Research Laboratories and Others) – Forecast To 2024
Key Players
Leading players profiled in the ADHD therapeutics market report include Teva Pharmaceutical, Shire, Pfizer Inc., Noven Pharmaceuticals Inc., Novartis AG, NEOS Therapeutics Inc., Janssen Global Services LLC, Highland Therapeutics Inc., Eli Lilly and Company, and Concordia International Corp., among others. Key players have incorporated numerous strategies such as mergers and acquisitions, partnerships/joint ventures, research and development activities, expansions, collaborations, and product developments to create a niche in the market.
Market Analysis
The global ADHD therapeutics market is predicted to grow at a healthy CAGR over the forecast period (2019-2024), as stated by the latest Market Research Future (MRFR) report. ADHD or attention deficit hyperactivity disorder is a common mental disorder that affects children, though it also affects many adults. Some of its common symptoms include impulsivity (hasty acts which happen at the moment without a thought), hyperactivity (an excessive movement which does not fit the setting), and inattention (not being capable of keeping focus).
This is a common condition which impacts self-control, focus, and other skills vital in daily life. It occurs due to differences in wiring and brain anatomy, and often this runs in families. ADHD impacts how children function in school as well as day to day life. Organization and planning, self-regulation, managing emotions, flexible thinking, and working memory are some skills children with this disorder struggle with. Although the exact risk factors as well as causes of this disorder are unknown but genetics plays a crucial role. ADHD is of three types depending on the symptoms. These include combined presentation, predominantly hyperactive-impulsive presentation, and predominantly inattentive presentation.
Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/1573
Various factors are propelling the ADHD therapeutics market growth. These factors, according to the latest MRFR report, include increasing use of preservatives and additives in children’s diet, growing use of diagnostic guidelines, changing value systems and evolving lifestyles impacting the quality of births, and prevalence of ADHD among children aged 4-17 years, and lack of standard diagnostic tests.
On the contrary, lack of availability of non-stimulant ADHD drugs across different locations may hamper the ADHD therapeutics market growth over the forecast period.
Market Segmentation
The MRFR report provides a complete segmental analysis of the ADHD therapeutics market report on the basis of distribution channel and drug type.
Based on drug type, the ADHD therapeutics market is segmented into non-stimulants and stimulants. The stimulants segment is further segmented into lisdexamfetamine, dextroamphetamine, methylphenidate, amphetamine, and others. The non-stimulants segment is further segmented into clonidine, guanfacine, bupropion, and atomoxetine.
Based on distribution channel, the ADHD therapeutics market is segmented into research laboratories, pharmacies, clinics, hospitals, and others.
April 2019: The US FDA (Food and Drug Administration) has permitted the marketing of the first-ever medical device, Monarch external Trigeminal Nerve Stimulation System to treat ADHD (attention deficit hyperactivity disorder). It is indicated for patients aged between 7-12 years who are not presently taking prescription medication for ADHD. This is the first non-drug ADHD treatment that has received marketing authorization from the FDA.
Regional Analysis
By region, the ADHD therapeutics market report covers the latest trends and growth opportunities across Europe, North America, the Asia Pacific, and the Middle East and Africa. Of these, North America will spearhead the market over the forecast period. Factors aiding growth in the region include high healthcare expenditure and growing prevalence of ADHD in the region in children.
The ADHD therapeutics market in Europe is predicted to have the second-largest share in the market over the forecast period. This is chiefly on account of the increased research and development activities for introducing effective drugs.
The ADHD therapeutics market in the APAC region is predicted to have a notable growth over the forecast period owing to growing awareness about the disease and also its available treatments.
On the flip side, the ADHD therapeutics market in the MEA is predicted to have a slow growth over the forecast period due to poor primary healthcare and low awareness in the region’s underdeveloped areas.
1.INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
2.RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH
3.MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
4.MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
5.GLOBAL ADHD THERAPEUTICS MARKET, BY DRUG TYPE
5.1 STIMULANTS
5.1.1 AMPHETAMINE
5.1.2 METHYLPHENIDATE
5.1.3 DEXTROAMPHETAMINE
6.GLOBAL ADHD THERAPEUTICS MARKET, BY AGE GROUP
6.1 PEDIATRIC AND ADOLESCENT
6.2 ADULTS
7.GLOBAL ADHD THERAPEUTICS MARKET, BY END USERS
7.1 SPECIALTY CLINICS
7.2 HOSPITAL PHARMACIES
7.3 RETAIL PHARMACIES
8.GLOBAL ADHD THERAPEUTICS MARKET, BY REGION
8.1 INTRODUCTION
8.2 AMERICA
8.2.1 NORTH AMERICA
8.2.1.1 US
9.COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 AMEDRA PHARMACEUTICALS LLC
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
11 CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
12 APPENDIX
Get Complete Report Details with Detail Tables and Figures @ https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
